Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Shares Outstanding (Diluted Average) (2020 - 2025)

Historic Shares Outstanding (Diluted Average) for BridgeBio Pharma (BBIO) over the last 6 years, with Q3 2025 value amounting to $191.9 million.

  • BridgeBio Pharma's Shares Outstanding (Diluted Average) rose 177.38% to $191.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $191.9 million, marking a year-over-year increase of 177.38%. This contributed to the annual value of $186.1 million for FY2024, which is 1430.32% up from last year.
  • According to the latest figures from Q3 2025, BridgeBio Pharma's Shares Outstanding (Diluted Average) is $191.9 million, which was up 177.38% from $190.5 million recorded in Q2 2025.
  • BridgeBio Pharma's Shares Outstanding (Diluted Average)'s 5-year high stood at $191.9 million during Q3 2025, with a 5-year trough of $144.4 million in Q4 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Diluted Average) was $161.7 million (2023), whereas its average is $165.5 million.
  • In the last 5 years, BridgeBio Pharma's Shares Outstanding (Diluted Average) soared by 2234.08% in 2021 and then fell by 4.74% in 2022.
  • BridgeBio Pharma's Shares Outstanding (Diluted Average) (Quarter) stood at $144.4 million in 2021, then increased by 2.16% to $147.5 million in 2022, then increased by 10.39% to $162.8 million in 2023, then rose by 14.3% to $186.1 million in 2024, then increased by 3.11% to $191.9 million in 2025.
  • Its last three reported values are $191.9 million in Q3 2025, $190.5 million for Q2 2025, and $190.1 million during Q1 2025.